# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹652 Cr** Q4 (+11.3%) · **₹2,545 Cr** FY26 (+15%) * **Net Debt to EBITDA:** **1.4x** (vs. 2.2x–2.3x YoY) * **Cash Flow Conversion:** **87%** FY26 normalized EBITDA-to-CFO ## B. Revenue & ARPP * **Scalability Drivers:** Robust annual top-line momentum was fueled by double-digit patient volume growth and steady improvements in average realization across the oncology network. * **Yield Optimization:** Management is targeting a **5% medical inflation adjustment** to support a **15% revenue growth guidance**, while intentionally shedding low-margin business to bolster long-term ARPP. * **Realization Discipline:** Growth was characterized by improved quality of earnings and better realization discipline, though specific volumes of foregone low-margin business remain unquantified. ## C. Margins & Profitability * **Margin Expansion:** Strong annual margin accretion of **70 bps** was driven by a favorable payor mix shift and a strategic pivot toward higher-margin business in the South, West, and East clusters. * **Asset Efficiency:** The flagship Bangalore KR facility demonstrates high capital efficiency, currently operating at a **ROCE of 30%+**. * **Quality of Earnings:** Profitability gains are being supported by a **100 bps payor mix shift** over the last two quarters, enhancing overall cash generation. ## D. Debt & Liquidity * **Deleveraging Success:** Significant reduction in leverage provides substantial headroom for expansion, remaining well below the internal ceiling of **2.5x**. * **Capital Structure:** Balance sheet strength was bolstered by a rights issue and debt repayment; interest costs are expected to trend lower from the current **8% average**. * **Cash Flow Profile:** High operating cash flow conversion was maintained despite a one-off **ESOP settlement** that temporarily impacted reported figures. --- # 2. Clinical & Technology Performance ## A. Specialized Case Management & Differentiation * **Clinical Leadership:** HCG continues to distinguish itself through the successful management of highly complex cases, leveraging a **35-year legacy** to maintain a competitive edge over multi-specialty peers. * **Advanced Treatment Modalities:** Demonstrated clinical excellence via ultra-personalized immuno-radiation (PULSAR) for geriatric patients and specialized cytoreductive surgeries with HIPEC for ovarian cancer. * **Academic & Surgical Recognition:** Global clinical standing reinforced by the publication of rare robotic-assisted urological procedures in international journals and the management of complex dual primary malignancies. ## B. Innovation & Technology * **Regional Technological Moat:** The commissioning of the North Bangalore facility introduces **MR-Linac technology**, establishing a first-mover advantage and technology-led differentiation in the region. ## C. Digital Transformation * **Strategic Patient Acquisition:** Aggressive investment in digital infrastructure aims to shift the mix toward owned channels, reducing long-term reliance on external referrals. * **Conversion Efficiency:** Digital initiatives are focused on urban and semi-urban markets to improve campaign ROI and convert brand trust into high-quality patient volumes. --- # 3. Operating Cluster Performance ## A. Regional Performance & Margin Outlook * **West Cluster Dominance:** Remains the primary revenue driver fueled by Gujarat and Maharashtra expansion; low utilization relative to the group average suggests significant organic headroom. * **South Cluster Maturity:** High-margin profile maintained despite Q4 moderation caused by a strategic pivot away from low-margin business and softer medical value travel. * **Expansion Opportunities:** Management identifies the West and East regions as the primary vehicles for future margin expansion, while the East benefits from clinician onboarding in Kolkata. * **Cohort Volatility:** Fluctuations in revenue-bucket margins are attributed to the **reclassification of centers** between cohorts rather than underlying operational declines. ## B. International & Strategic Growth * **Kenya Outperformance:** Exceptional annual growth driven by high-end modalities including radiation oncology and PET services. * **Operational Optimization:** Growth is being steered by a refined payor mix, oncology specialization, and capital deployment into **higher returns markets**. ## C. Utilization & Productivity * **Blended Metric Transition:** Shifted to a comprehensive utilization metric factoring in chemo beds, OTs, and radiation machines to better reflect revenue potential beyond traditional occupancy. * **Network Optimization:** Strategy focuses on leveraging the **25-hospital network** across **18 cities** through improved clinical productivity and stronger referral ecosystems. --- # 4. Capacity & Network Expansion ## A. Key Figures * **Long-term Capacity Target:** **~1,000 Beds** by FY30 (600 Brownfield / 400 Greenfield) * **Day-Care Expansion:** **8-10 New Locations** over the next 24 months ## B. Brownfield & Internal Growth Strategy * **Core Growth Engine:** Management expects the vast majority of growth over the next three years to be driven by existing hospitals and internal expansions. * **Strategic Relocation:** The Whitefield project is being transitioned to a larger facility to capitalize on high localized market demand. * **High-Return Focus:** Near-term expansion prioritizes brownfield opportunities in high-potential centers to ensure faster ramp-up and superior returns. ## C. Greenfield & Network Pipeline * **Bangalore Footprint:** Operations have commenced at the North Bangalore facility, a comprehensive oncology center offering specialized services including BMT and PET-CT imaging. * **New Facility Development:** The company is actively seeking an alternate location for a new facility with a capacity of **120 to 130 beds** to address infrastructure gaps. * **Geographic Evaluation:** Selective greenfield expansion is being evaluated across **10 to 12 cities**, including Pune, Surat, and Lucknow, contingent on talent availability and market potential. ## D. Asset-Light & Operational Initiatives * **Technology Financing:** HCG is utilizing an asset-light model for its North Bangalore facility, acquiring advanced **MR-Linac** technology on a pay-per-use basis. * **Clinical Talent Acquisition:** Growth will be supported by the addition of **23 oncologists** in Q4 to bolster clinical depth across the network. * **Market Reach:** Expansion strategy includes doubling the Day-Care center footprint and increasing outreach centers to accelerate sales and market penetration. --- # 5. Strategic Initiatives & M&A ## A. Key Figures * **Transaction Terms:** **75%** Upfront payment · **25%** Deferred over 18 months * **Rights Issue Proceeds:** **₹425 Cr** Total capital raised ## B. Core Oncology Focus & Divestment Strategy * **Strategic Realignment:** The exit from the fertility business (Milann) after **13 years** enables management to reallocate bandwidth and capital exclusively toward the core oncology network. * **Operational Rationale:** Divestment follows a period of contraction where the fertility footprint shrank from **9 to 6 centers**, with margins stagnating near break-even levels. * **Execution Timeline:** The sale to Inviga Healthcare Fund, finalized via a competitive process, is expected to close within **Q1 FY27**. ## C. Growth & Capital Allocation * **Strengthened Balance Sheet:** Successful completion of the rights issue provides the necessary liquidity for clinical infrastructure upgrades and capacity expansion. * **Inorganic Pipeline:** Management is actively evaluating M&A opportunities beyond the **two existing Bangalore facilities** to complement organic growth, though no definitive agreements are currently in place. --- # 6. Risks & Healthcare Externalities ## A. Geopolitical Impact * **Revenue Headwinds:** Top-line growth was tempered by a strategic reduction in low-margin business and a decline in medical value travel. * **Regional Conflict Sensitivity:** Patient volumes in the West and South clusters were adversely affected by the ongoing **Middle East conflict**. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Growth:** **11%** Q4 YoY · **15%** Full-Year FY25 · **15-20%** Medium-term Target * **ROCE:** **14%** Current Pre-tax · **20%** 4-5 Year Target ## B. Revenue Growth Targets * **Multi-Pronged Scaling:** Management targets sustained double-digit growth through occupancy enhancement, sales acceleration, and expanded ORC outreach. * **Expansion Strategy:** Growth trajectory supported by deepening existing market presence and pursuing **inorganic expansion** opportunities. * **Structural Demand:** Long-term outlook underpinned by a strong brand legacy and rising market demand due to the increasing incidence of cancer. ## C. Margin & Profitability Outlook * **Quality of Earnings:** Strategic pivot toward "holistic profitable growth," prioritizing margin expansion, cash generation, and improved returns over volume alone. * **Mix Normalization:** Transition to high-margin business expected to stabilize within **two quarters**, aided by a new Head of International Sales focused on recovering medical tourism volumes. * **Operational Efficiency:** Margin and return improvements anticipated across current business buckets, supported by cost optimization in procurement and leases. ## D. Long-term ROCE & Strategic Levers * **Capital Efficiency:** Current return profile driven by center maturity and disciplined capital allocation, with a clear roadmap to reach the **20%** benchmark. * **Forward Visibility:** Management indicates that strategic levers for **FY27** are already visible, ensuring a transition into the next phase of profitable growth.